Bortezomib will improve the level or result of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Elevated flibanserin adverse outcomes could manifest if coadministered with a number of weak CYP3A4 inhibitors. Other outcomes, like a skin rash, is probably not major but might result in problem. https://sb22500265431.blogofoto.com/57857681/the-smart-trick-of-dup-747-that-nobody-is-discussing